News
Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback